Pharmacokinetic interaction between multiple-dose venlafaxine and single-dose lithium

Journal of Clinical Pharmacology

Volumn 36, Issue 2, 1996, Pages 175-181

  Troy, Steven M ^a   Parker, Vernon D ^a   Hicks, David R ^a   Boudino, F Douglas ^b   Chiang, Soong T ^a  

^a WYETH AYERST RESEARCH   (United States)

^b UNIVERSITY OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LITHIUM CARBONATE; VENLAFAXINE;

ADULT; ANOREXIA; ARTICLE; ASTHENIA; CLINICAL TRIAL; DEPRESSION; DRUG ABSORPTION; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG EFFECT; DRUG SAFETY; DRUG SCREENING; HUMAN; HUMAN EXPERIMENT; MALE; NAUSEA; NORMAL HUMAN; SOMNOLENCE;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CYCLOHEXANOLS; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; HUMANS; LITHIUM; MALE; MIDDLE AGED; SEROTONIN UPTAKE INHIBITORS;

EID: 0029881025     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1552-4604.1996.tb04183.x     Document Type: Article

References (25)

1. Moyer JA, Muth EA, Haskins JT, Lappe RW, Sigg EB: In vivo antidepressant profiles of the novel bicyclic compounds WY-45030 and WY-45881 (abstract). Soc Neurosci Abstr 1984; 10:261.
2. Haskins JT, Moyer JA, Muth EA, Sigg EB: DMI, WY-45,030, WY-45,881, and ciramadol inhibit locus ceruleus neuronal activity. Eur J Pharmacol 1985; 115:139-146.
3. Muth EA, Haskins JT, Moyer JA, Husband GE, Nielsen ST, Sigg EB: Antidepressant biochemical profile of the novel bicyclic compound WY-45030, an ethyl cyclohexanol derivative. Biochem Pharmacol 1986; 35:4493-4497.
4. Rudorfer MV, Potter WZ: Antidepressants: a comparative review of the clinical pharmacology and therapeutic use of the "newer" versus the "older" drugs. Drugs 1989; 37:713-738.
5. Muth EA, Moyer JA, Haskins JT, Andree TH, Husbands GEM: Biochemical, neurophysiological, and behavioral effects of WY-45233 and other identified metabolites of the antidepressant venlafaxine. Drug Dev Res 1991; 23:191-199.
6. Muth EA, Moyer JA, Andree TH: A pharmacological profile of WY-45233, the major metabolite in humans of the novel bicyclic antidepressant candidate WY-45030 (abstract). Soc Neurosci Abstr 1986; 12:473.
7. Klamerus KJ, Maloney K, Rudolph RL, Sisenwine SF, Jusko WJ, Chiang ST: Introduction of a composite parameter to the pharmacokinetics of venlafaxine and its active O-desmethyl metabolite. J Clin Pharmacol 1992; 32:716-724.
8. 14C-venlafaxine in mouse, rat, dog, rhesus monkey and man. Xenobiotica 1993; 23:349-359.
9. Otton SV, Ball SE, Cheung SW, Inaba T, Sellers EM: Comparative inhibition of the polymorphic enzyme CYP2D6 by venlafaxine and other 5-HT uptake inhibitors (abstract). Clin Pharmacol Ther 1994; 55-141.
10. Otton SV, Ball SE, Inaba T, Sellers EM: Interaction of venlafaxine, a new antidepressant, with CYP2D6 in human liver microsomes (abstract). Neuropharmacology 1994; 10(Suppl 2):219S.
11. Frost RE, Messiha FS: Clinical use of lithium salts. Brain Res Bull 1983; 11:219-231.
12. Bunney WE Jr, Garland-Bunney BL: Mechanisms of action of lithium in affective illness: basic and clinical implications. In, Meltzer HY (ed.): Psychopharmacology: The Third Generation of Progress. New York: Raven Press, 1987; 553-565.
13. Amdisen A: Serum level monitoring and clinical pharmacokinetics of lithium. Clin Pharmacokinet 1977; 2:73-92.
14. Caldwell HC, Westlake WJ, Schriver RC, Bumbier EE: Steady-state lithium blood level fluctuations in man following administration of a lithium carbonate conventional and control-release dosage form. J Clin Pharmacol 1981; 21:106-109.
15. Johnson G: Lithium. Med J Aust 1984; 141:595-601.
16. Schou M: Lithium treatment: a refresher course. Br J Psychiatry 1986; 149:541-547.
17. Salama AA, Shafey M: A case of severe lithium toxicity induced by combined fluoxetine and lithium carbonate (letter). Am J Psychiatry 1989; 146:278.
18. Noveske FG, Hahn KR, Flynn RJ: Possible toxicity of combined fluoxetine and lithium (letter). Am J Psychiatry 1989; 146: 1515.
19. Mason RW, McQueen EG, Keary PJ, James N: Pharmacokinetics of lithium: elimination half-time, renal clearance and apparent volume of distribution in schizophrenia. Clin Pharmacokinet 1978; 3:241-246.
20. Hicks DR, Wolaniuk D, Russell A, Cavanaugh N, Kraml M: A high performance liquid chromatographic method for the simultaneous determination of venlafaxine and O-desmethylvenlafaxine in biological fluids. Ther Drug Monit 1994; 17:101-107.
21. Metzler CM, Elfring GL, McEwan AJ: A package of computer programs for pharmacokinetic modeling. Biometrics 1974; 30:562-563.
22. Jusko WJ: Guidelines for collection and analysis of pharmacokinetic data. In, Evans W, Schentag JJ, Jusko WJ (eds.): Applied Pharmacokinetics. Spokane, WA: Academic Press, 1986.
23. Schuirmann DJ: A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm 1987; 15:657-680.
24. Weiner IM: Excretion of drugs by the kidney. In, Brodie BB, Gillette JR, Ackerman HS (eds.): Handbook of Experimental Pharmacology. Heidelberg: Springer-Verlag, 1971;328-353.
25. Rennick BR: Renal tubule transport of organic cations. Am J Physiol 1981; 240:F83-F89.